2 not yet recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 2 |
Follow Shaodong Hong: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC Toripalimab, Sacituzumab Tirumotecan (SKB264) - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Shaodong Hong | 30 | 2026-10-01 | 2026-09-15 |
| Paclitaxel Polymeric Micelles Plus Ivonescimab in Recurrent or Refractory SCLC Paclitaxel Polymeric Micelles, Ivonescimab - SCLC, Recurrent | Phase 2 | Not yet recruiting | Shaodong Hong | 47 | 2026-10-01 | 2026-09-15 |
Carcinoma, Non-Small-Cell Lung (1) · Recurrence (1) · Small Cell Lung Carcinoma (1)
toripalimab (1)
China (1)